Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal palivizumab for prevention of experimental RSV infection
NL-OMON55009Phase 2Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of palivizumab in respiratory syncytial virus disease (RSV) (3 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Productive infection in Study A and Viral load AUC in Study B. Planned start Apr 2021; status: withdrawn.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON55009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55009.